NCOR1

Summary

NCOR1 (nuclear receptor corepressor 1, HGNC:7672) is a protein-coding gene on chromosome 17p12-p11.2, encoding Nuclear receptor corepressor 1 (O75376). Mediates transcriptional repression by certain nuclear receptors.

This gene encodes a protein that mediates ligand-independent transcription repression of thyroid-hormone and retinoic-acid receptors by promoting chromatin condensation and preventing access of the transcription machinery. It is part of a complex which also includes histone deacetylases and transcriptional regulators similar to the yeast protein Sin3p. This gene is located between the Charcot-Marie-Tooth and Smith-Magenis syndrome critical regions on chromosome 17. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene are found on chromosomes 17 and 20.

Source: NCBI Gene 9611 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 7
• Clinical variants (ClinVar): 364 total — 1 likely-pathogenic
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 13 cancer types
• Transcription factor: yes — 97 downstream targets (CollecTRI)
• MANE Select transcript: NM_006311

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7672
Approved symbol	NCOR1
Name	nuclear receptor corepressor 1
Location	17p12-p11.2
Locus type	gene with protein product
Status	Approved
Aliases	N-CoR, hCIT529I10, TRAC1, hN-CoR, KIAA1047, MGC104216, PPP1R109
Ensembl gene	ENSG00000141027
Ensembl biotype	protein_coding
OMIM	600849
Entrez	9611

Gene structure

Transcript identifiers

Ensembl transcripts: 49 — 35 protein_coding, 11 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000268712, ENST00000395848, ENST00000395849, ENST00000395851, ENST00000411510, ENST00000430577, ENST00000436068, ENST00000436828, ENST00000458113, ENST00000460276, ENST00000464381, ENST00000466825, ENST00000470782, ENST00000472189, ENST00000579573, ENST00000579606, ENST00000579974, ENST00000580554, ENST00000580617, ENST00000582357, ENST00000582565, ENST00000583226, ENST00000583234, ENST00000584872, ENST00000585296, ENST00000603989, ENST00000704743, ENST00000704744, ENST00000704745, ENST00000917643, ENST00000917644, ENST00000917645, ENST00000917646, ENST00000917647, ENST00000917648, ENST00000917649, ENST00000917650, ENST00000917651, ENST00000917652, ENST00000917653, ENST00000917654, ENST00000917655, ENST00000917656, ENST00000917657, ENST00000917658, ENST00000917659, ENST00000917660, ENST00000917661, ENST00000917662

RefSeq mRNA: 3 — MANE Select: NM_006311 NM_001190438, NM_001190440, NM_006311

CCDS: CCDS11175, CCDS54094, CCDS54095

Canonical transcript exons

ENST00000268712 — 46 exons

Exon	Start	End
ENSE00001930630	16215362	16215534
ENSE00002329939	16101250	16101757
ENSE00003468730	16029157	16032483
ENSE00003992307	16194462	16194639
ENSE00003992309	16057907	16058064
ENSE00003992312	16080607	16080727
ENSE00003992313	16098367	16098496
ENSE00003992314	16138158	16138212
ENSE00003992316	16062105	16062270
ENSE00003992317	16108786	16108912
ENSE00003992319	16137311	16137412
ENSE00003992322	16070165	16070525
ENSE00003992323	16158760	16158873
ENSE00003992324	16126082	16126206
ENSE00003992326	16061401	16061894
ENSE00003992327	16048845	16048988
ENSE00003992331	16075534	16075702
ENSE00003992332	16040441	16040494
ENSE00003992334	16139008	16139186
ENSE00003992335	16149451	16149517
ENSE00003992336	16164979	16165161
ENSE00003992337	16143606	16143696
ENSE00003992339	16072145	16072228
ENSE00003992342	16079964	16080064
ENSE00003992343	16080408	16080509
ENSE00003992345	16186554	16186687
ENSE00003992346	16119423	16119485
ENSE00003992350	16046951	16047093
ENSE00003992353	16067894	16068121
ENSE00003992357	16064870	16065019
ENSE00003992358	16071409	16071665
ENSE00003992359	16034765	16034944
ENSE00003992362	16073429	16073569
ENSE00003992363	16117888	16118027
ENSE00003992368	16146376	16146548
ENSE00003992369	16086282	16086442
ENSE00003992370	16091863	16092058
ENSE00003992371	16065485	16065694
ENSE00003992372	16057514	16057737
ENSE00003992373	16171803	16171995
ENSE00003992376	16151946	16151998
ENSE00003992378	16064068	16064187
ENSE00003992380	16153339	16153395
ENSE00003992381	16039433	16039654
ENSE00003992382	16058471	16058599
ENSE00003992383	16121052	16121269

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 98.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.4131 / max 475.4363, expressed in 1814 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164722	28.3598	1814
164715	0.0533	4

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.12	gold quality
colonic epithelium	UBERON:0000397	97.49	gold quality
calcaneal tendon	UBERON:0003701	96.95	gold quality
ventricular zone	UBERON:0003053	96.37	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.92	gold quality
adrenal tissue	UBERON:0018303	95.60	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	95.58	gold quality
mucosa of transverse colon	UBERON:0004991	95.34	gold quality
cortical plate	UBERON:0005343	95.33	gold quality
buccal mucosa cell	CL:0002336	95.31	gold quality
ganglionic eminence	UBERON:0004023	95.27	gold quality
corpus callosum	UBERON:0002336	94.99	gold quality
stomach	UBERON:0000945	94.87	gold quality
rectum	UBERON:0001052	94.83	gold quality
bone marrow cell	CL:0002092	94.74	gold quality
body of uterus	UBERON:0009853	94.71	gold quality
body of stomach	UBERON:0001161	94.58	gold quality
transverse colon	UBERON:0001157	94.53	gold quality
renal medulla	UBERON:0000362	94.51	gold quality
nipple	UBERON:0002030	94.48	gold quality
stromal cell of endometrium	CL:0002255	94.43	gold quality
skin of leg	UBERON:0001511	94.29	gold quality
small intestine	UBERON:0002108	94.27	gold quality
fundus of stomach	UBERON:0001160	94.20	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.20	gold quality
ascending aorta	UBERON:0001496	94.19	gold quality
thoracic aorta	UBERON:0001515	94.17	gold quality
descending thoracic aorta	UBERON:0002345	94.17	gold quality
cerebellar hemisphere	UBERON:0002245	94.14	gold quality
monocyte	CL:0000576	94.08	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	25.49
E-GEOD-100618	no	1239.59
E-GEOD-70580	no	1226.51
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

97 targets.

Target	Regulation
ABCA1
ACHE
ADAM2
ALG3
AR	Activation
ASCL2
BACE1
BMAL1
CCND1	Repression
CCR4
CD44
CD74
CDK9
CDKN1A
CGA	Unknown
CNOT2
COX8A
CPT1A	Repression
CREBBP
CRH
CRTC1
CXCL10
CYP19A1
CYP21A1P
CYP26A1
CYP3A4
DACH1
DEPP1
DIO1
ERVW-4

Upstream regulators (CollecTRI, top): AR, ESR1, ESR2, HESX1, NCOR1, NFKB1, POU1F1, POU4F2, RELA, THAP7, VDR

miRNA regulators (miRDB)

135 targeting NCOR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917

Literature-anchored findings (GeneRIF, showing 40)

• Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation (PMID:11903058)
• Results show that the N-CoR-HDAC3 complex inhibits JNK activation through the associated GPS2 subunit and thus could potentially provide an alternative mechanism for hormone-mediated antagonism of AP-1 function. (PMID:11931768)
• Mammalian PRP4 kinase copurifies and interacts with components of both the U5 snRNP and the N-CoR deacetylase complexes. (PMID:12077342)
• These results demonstrate that AR, in contrast to other SHRs, is regulated by NCoR (PMID:12089345)
• Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. (PMID:12150997)
• recruited by prohibitin for transcriptional repression (PMID:12466959)
• N-CoR functions not merely as a repressor of basal transcription, but rather as a modulator of both basal and ligand-activated transcription of genes controlled by RAR/RXR heterodimers in a dose-dependent manner (PMID:12648520)
• N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor (PMID:12861000)
• associates with CHD1 and histone deacetylase as well as with RNA splicing proteins (PMID:12890497)
• N-CoR utilizes repression domains I and III for interaction and co-repression with ETO (PMID:15377655)
• THAP7 coimmunoprecipitates with histone deacetylase 3 and the nuclear hormone receptor corepressor and represses transcription (PMID:15561719)
• NCoR is a physiological regulator of the AR; the N-terminal surface of the AR-mediating NCoR recruitment was distinct from tau5 and from the FXXLF motif that mediates agonist-induced N-C-terminal interaction (PMID:15598662)
• the DAD domain of N-CoR is singularly essential for repression by the thyroid hormone receptor (PMID:15695367)
• the N-CoR/HDAC3 complex has a role in regulating the expression of genes involved in circadian rhythm by functioning as corepressor for Rev-erbalpha (PMID:15761026)
• N-CoR and SMRT play an active role in preventing tamoxifen from stimulating proliferation in breast cancer cells through repression of a subset of target genes involved in ERalpha function and cell proliferation (PMID:15802375)
• N-CoR together with JMJD2A could play a role in repressing achaete scute-like homologue 2 (ASCL2) expression in various tissues. (PMID:16024779)
• mechanism by which the estrogen-ER complex markedly reduces the level of N-CoR through a process involving the up-regulation of Siah2 and the subsequent targeting of N-CoR for proteasomal degradation (PMID:16141343)
• SAFB1 was shown to interact directly with the nuclear receptor corepressor N-CoR. (PMID:16195251)
• N-CoR and TRbeta cooperate in the regulation of the TSHbeta gene and this ligand-dependent repression is mediated by the LXXLL motif in N-CoR (PMID:16216492)
• SMRT and N-CoR corepressors are involved in transcriptional regulation by both agonist- and antagonist-bound AR and regulate the magnitude of hormone response, at least in part, by competing with coactivators. (PMID:16373395)
• Results provide evidence to show that the N-CoR/HDAC3 co-repressor complex is involved in the aberrant transcription regulation in PML-RARalpha-expressing cells. (PMID:16730330)
• RB7 and butyrate induce dissociation of HDAC3 (but not HDAC1 or HDAC2) and its adaptor protein NCoR. (PMID:16849648)
• The repression mechanisms by the nuclear receptor corepressor (N-CoR) of steroid hormone receptor (SHR)-mediated transactivation were examined. (PMID:16914745)
• first report of a direct interaction between N-CoR and CBP, and suggests that the role of N-CoR in mediating transcriptional events may be more complex than previously anticipated (PMID:17073437)
• Data show that IKKalpha phosphorylates the homologous N-CoR corepressor in serines 2345 and 2348 creating a functional 14-3-3 binding domain (RK(p)S(2348)KSP). (PMID:17630505)
• Data support a role for N-CoR in erythroid differentiation and suggest that N-CoR is required for the induction of a key enzyme involved in heme synthesis. (PMID:17768398)
• both SMRT and N-CoR are limited in cells and knocking down either of them results in co-repressor-free TR and consequently de-repression of TR target genes (PMID:18052923)
• Vitamin D receptor (VDR) with the retinoid X receptor (RXR) recruits NCoR and SMRT strictly in a VDR agonist-dependent manner. (PMID:18362166)
• ETO family member-mediated oligomerization and repression can be distinct events and that interaction between ETO family members and hSIN3B or N-CoR may not necessarily strengthen transcriptional repression. (PMID:18586123)
• SMRT and NCoR have important roles in the regulation of beta-catenin-TCF4-mediated gene transcription (PMID:18632669)
• A point mutation (S296R) in the amino-terminal domain of the androgen receptor (AR) can decrease the ligand specificity of the AR and alter the interaction between serine296arginine and the nuclear receptor co-repressor 1 (N-coR). (PMID:18637017)
• Data show that, at sufficiently high concentration, the NR corepressor (NCoR) influences the activity of the liver X receptor (LXR) even in the presence of a potent full agonist that destabilizes NCoR binding. (PMID:18669643)
• apoptotic cells induce PPARgamma sumoylation to attenuate the removal of NCoR, thereby blocking transactivation of NF-kappaB. (PMID:18832723)
• These findings show that AR antagonists can enhance corepressor recruitment by stabilizing a distinct antagonist conformation of the AR coactivator/corepressor binding site. (PMID:18852122)
• NCoR was expressed in the cytoplasm of colorectal carcinoma-associated myofibroblasts, but was rarely noted in myofibroblasts of normal mucosa or adenomas. (PMID:19048289)
• NCOR1 is a selective regulator of nuclear receptors, notably PPARgamma and VDR, and contributes to their loss of sensitivity. (PMID:19126649)
• Up-regulation of nuclear receptor corepressor is associated with progestin-induced growth suppression of endometrial hyperplasia and carcinoma (PMID:19414341)
• NCoR1 expression is required to maintain IEC in a proliferative state, and PEDF is a novel transcriptional target for NCoR1 repressive action (PMID:19608741)
• NCOR1 protein expression level predicts response to endocrine therapy as first-line treatment for breast cancer patients on relapse. (PMID:19781322)
• hPPARalpha SUMOylation on lysine 185 down-regulates its trans-activity through the selective recruitment of NCoR (PMID:19955185)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ncor1	ENSDARG00000035285
mus_musculus	Ncor1	ENSMUSG00000018501
rattus_norvegicus	Ncor1	ENSRNOG00000055246
caenorhabditis_elegans		WBGENE00001565

Paralogs (1): NCOR2 (ENSG00000196498)

Protein

Protein identifiers

Nuclear receptor corepressor 1 — O75376 (reviewed: O75376)

All UniProt accessions (13): O75376, A0A994J5B8, C9JAP0, E7EVK1, E7EVU5, E7EW50, H0Y459, J3KRE4, J3KS29, J3KS51, J3KT44, J3QKP0, S4R380

UniProt curated annotations — full annotation on UniProt →

Function. Mediates transcriptional repression by certain nuclear receptors. Part of a complex which promotes histone deacetylation and the formation of repressive chromatin structures which may impede the access of basal transcription factors. Participates in the transcriptional repressor activity produced by BCL6. Recruited by ZBTB7A to the androgen response elements/ARE on target genes, negatively regulates androgen receptor signaling and androgen-induced cell proliferation. Mediates the NR1D1-dependent repression and circadian regulation of TSHB expression. The NCOR1-HDAC3 complex regulates the circadian expression of the core clock gene ARTNL/BMAL1 and the genes involved in lipid metabolism in the liver.

Subunit / interactions. Forms a large corepressor complex that contains SIN3A/B and histone deacetylases HDAC1 and HDAC2. This complex associates with the thyroid receptor (TR) and the retinoid acid receptor (RAR) in the absence of ligand. Interacts directly with RARA; the interaction is facilitated with RARA trimethylation. Component of the N-Cor repressor complex, at least composed of CBFA2T3, HEXIM1, NCOR1, NCOR2, HDAC3, TBL1X, TBL1XR1, CORO2A and GPS2. Interacts with ZBTB33; the interaction serves to recruit the N-CoR complex to promoter regions containing methylated CpG dinucleotides. Interacts with TRIM28 and KDM3A. Interacts (via the RD1 domain) with BAZ1A (via its N-terminal); the interaction corepresses a number of NCOR1-regulated genes. Interacts with BCL6, C1D, DACH1, HEXIM1, HDAC7, RORA, RORC, SAP30, SIAH2, SIN3A and SIN3B. May interact with DEAF1. Interacts with RXRA. Interacts with SETD5. Interacts with VDR. Interacts with ZBTB7A. Interacts with AR. Interacts with HDAC3.

Subcellular location. Nucleus.

Post-translational modifications. Ubiquitinated; mediated by SIAH2 and leading to its subsequent proteasomal degradation.

Domain organisation. The N-terminal region contains three independent domains that are capable of mediating transcriptional repression (RD1, RD2 and RD3). The C-terminal region contains two separate nuclear receptor-interacting domains (ID1 and ID2), each of which contains a conserved sequence referred to as the CORNR box. This motif is necessary and sufficient for binding to unligated nuclear hormone receptors, while sequences flanking the CORNR box determine the precise nuclear hormone receptor specificity.

Similarity. Belongs to the N-CoR nuclear receptor corepressors family.

Isoforms (3)

UniProt ID	Names	Canonical?
O75376-1	1	yes
O75376-2	2
O75376-3	3, b

RefSeq proteins (3): NP_001177367, NP_001177369, NP_006302* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001005	SANT/Myb	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR017884	SANT_dom	Domain
IPR017930	Myb_dom	Domain
IPR031557	N-CoR_GPS2_interact	Domain
IPR051571	N-CoR_corepressor	Family

Pfam: PF00249, PF15784

UniProt features (113 total): compositionally biased region 28, modified residue 26, region of interest 21, sequence conflict 10, cross-link 6, helix 5, splice variant 5, strand 3, coiled-coil region 3, short sequence motif 3, domain 2, chain 1

Structure

Experimental structures (PDB)

27 structures.

PDB	Method	Resolution (Å)
6XZZ	X-RAY DIFFRACTION	1.39
8FKC	X-RAY DIFFRACTION	1.42
6XYX	X-RAY DIFFRACTION	1.44
6Y17	X-RAY DIFFRACTION	1.56
8DKV	X-RAY DIFFRACTION	1.59
6ONI	X-RAY DIFFRACTION	1.8
8FHE	X-RAY DIFFRACTION	1.8
8FHG	X-RAY DIFFRACTION	1.8
8FKF	X-RAY DIFFRACTION	1.82
8DKN	X-RAY DIFFRACTION	1.95
6WMS	X-RAY DIFFRACTION	2
8FKE	X-RAY DIFFRACTION	2.02
3KMZ	X-RAY DIFFRACTION	2.1
9O9N	X-RAY DIFFRACTION	2.1
8FKG	X-RAY DIFFRACTION	2.12
8FKD	X-RAY DIFFRACTION	2.22
4MDD	X-RAY DIFFRACTION	2.4
6ZBU	X-RAY DIFFRACTION	2.46
8D8I	X-RAY DIFFRACTION	2.5
6WMQ	X-RAY DIFFRACTION	2.55
3N00	X-RAY DIFFRACTION	2.6
3H52	X-RAY DIFFRACTION	2.8
9OLC	X-RAY DIFFRACTION	2.83
4WVD	X-RAY DIFFRACTION	2.9
6XXS	X-RAY DIFFRACTION	3.25
8AS9	X-RAY DIFFRACTION	3.4
2EQR	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75376-F1	41.40	0.04

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (32): 172, 224, 999, 1111, 1195, 1196, 1249, 1263, 1281, 1322, 1336, 1367, 1412, 1450, 1472, 1592, 1977, 1981, 2102, 2120 …

Function

Pathways and Gene Ontology

Reactome pathways

68 pathways

ID	Pathway
R-HSA-1251985	Nuclear signaling by ERBB4
R-HSA-1989781	PPARA activates gene expression
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis
R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-3214815	HDACs deacetylate histones
R-HSA-350054	Notch-HLH transcription pathway
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-383280	Nuclear Receptor transcription pathway
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-9022537	Loss of MECP2 binding ability to the NCoR/SMRT complex
R-HSA-9022692	Regulation of MECP2 expression and activity
R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
R-HSA-9609690	HCMV Early Events
R-HSA-9623433	NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
R-HSA-9707564	Cytoprotection by HMOX1
R-HSA-9707616	Heme signaling
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-9931509	Expression of BMAL (ARNTL), CLOCK, and NPAS2
R-HSA-9933387	RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)
R-HSA-1236394	Signaling by ERBB4
R-HSA-1266738	Developmental Biology
R-HSA-1368071
R-HSA-1430728	Metabolism
R-HSA-157118	Signaling by NOTCH
R-HSA-1592230	Mitochondrial biogenesis

MSigDB gene sets: 390 (showing top): GOBP_CIRCADIAN_RHYTHM, REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, PID_HDAC_CLASSI_PATHWAY, MODULE_97, REACTOME_SIGNALING_BY_NOTCH, GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, GOBP_BEHAVIOR, TGCGCANK_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, AREB6_03, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, KENNY_CTNNB1_TARGETS_UP, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS

GO Biological Process (12): negative regulation of transcription by RNA polymerase II (GO:0000122), chromatin organization (GO:0006325), locomotor rhythm (GO:0045475), negative regulation of glycolytic process (GO:0045820), negative regulation of DNA-templated transcription (GO:0045892), negative regulation of fatty acid metabolic process (GO:0045922), negative regulation of JNK cascade (GO:0046329), spindle assembly (GO:0051225), negative regulation of androgen receptor signaling pathway (GO:0060766), negative regulation of miRNA transcription (GO:1902894), regulation of ketone metabolic process (GO:0010565), rhythmic process (GO:0048511)

GO Molecular Function (8): transcription cis-regulatory region binding (GO:0000976), transcription corepressor activity (GO:0003714), nuclear receptor binding (GO:0016922), histone deacetylase binding (GO:0042826), nuclear thyroid hormone receptor binding (GO:0046966), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (9): histone deacetylase complex (GO:0000118), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), membrane (GO:0016020), transcription repressor complex (GO:0017053), mitotic spindle (GO:0072686), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-18 pathways:

Category	Pathways
Generic Transcription Pathway	2
NR1H2 and NR1H3-mediated signaling	2
Signaling by ERBB4	1
Regulation of lipid metabolism by PPARalpha	1
Signaling by NOTCH1	1
Mitochondrial biogenesis	1
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1
Signaling by NOTCH1 PEST Domain Mutants in Cancer	1
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	1
Chromatin modifying enzymes	1
Adipogenesis	1
Metabolism of lipids	1
Activation of HOX genes during differentiation	1
Loss of function of MECP2 in Rett syndrome	1
Transcriptional Regulation by MECP2	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
negative regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
cellular component organization	1
locomotory behavior	1
circadian behavior	1
glycolytic process	1
regulation of glycolytic process	1
negative regulation of purine nucleotide catabolic process	1
negative regulation of carbohydrate metabolic process	1
negative regulation of ATP metabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
fatty acid metabolic process	1
regulation of fatty acid metabolic process	1
negative regulation of lipid metabolic process	1
negative regulation of small molecule metabolic process	1
JNK cascade	1
negative regulation of MAPK cascade	1
regulation of JNK cascade	1
spindle organization	1
chromosome segregation	1
membraneless organelle assembly	1
androgen receptor signaling pathway	1
negative regulation of intracellular steroid hormone receptor signaling pathway	1
regulation of androgen receptor signaling pathway	1
miRNA transcription	1
regulation of miRNA transcription	1
negative regulation of miRNA metabolic process	1
regulation of metabolic process	1
ketone metabolic process	1
biological_process	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
transcription coregulator activity	1
RNA polymerase II-specific DNA-binding transcription factor binding	1
enzyme binding	1
nuclear receptor binding	1

Protein interactions and networks

STRING

4168 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NCOR1	HDAC3	O15379	997
NCOR1	HDAC1	Q13547	997
NCOR1	TBL1Y	Q9BQ87	997
NCOR1	TBL1X	O60907	996
NCOR1	TBL1XR1	Q9BZK7	996
NCOR1	SIN3A	Q96ST3	995
NCOR1	HDAC4	P56524	993
NCOR1	MECP2	P51608	992
NCOR1	GPS2	Q13227	992
NCOR1	TAB2	Q9NYJ8	992
NCOR1	SIRT1	Q96EB6	990
NCOR1	NR1D1	P20393	990
NCOR1	RARA	P10276	989
NCOR1	ESR1	P03372	987
NCOR1	PPARG	P37231	986

IntAct

285 interactions, top by confidence:

A	B	Type	Score
GPS2	HDAC3	psi-mi:“MI:0914”(association)	0.900
RARA	NCOR1	psi-mi:“MI:0914”(association)	0.800
RARA	NCOR1	psi-mi:“MI:0407”(direct interaction)	0.800
HDAC3	NCOR1	psi-mi:“MI:0915”(physical association)	0.800
NCOR1	RARA	psi-mi:“MI:0915”(physical association)	0.800
HDAC3	TBL1X	psi-mi:“MI:0914”(association)	0.760
RUNX1T1	NCOR1	psi-mi:“MI:0407”(direct interaction)	0.720
RUNX1T1	NCOR1	psi-mi:“MI:0915”(physical association)	0.720
RUNX1T1	NCOR1	psi-mi:“MI:0914”(association)	0.720
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
NCOR1	SKI	psi-mi:“MI:0915”(physical association)	0.670
PPARA	NCOR1	psi-mi:“MI:0407”(direct interaction)	0.660
HDAC3	AKAP8	psi-mi:“MI:0914”(association)	0.650
AKAP8	HDAC3	psi-mi:“MI:0914”(association)	0.650
HDAC3	KDM1A	psi-mi:“MI:0914”(association)	0.650
NR1H3	NCOR1	psi-mi:“MI:0407”(direct interaction)	0.640
NCOR1	NR1H3	psi-mi:“MI:0914”(association)	0.640
ESR1	TRIM24	psi-mi:“MI:0914”(association)	0.640
TBL1XR1	HDAC3	psi-mi:“MI:0914”(association)	0.640
NR1H3	NCOR1	psi-mi:“MI:0914”(association)	0.640
NCOR1	SMARCA4	psi-mi:“MI:0915”(physical association)	0.630
NR1D1	NCOR1	psi-mi:“MI:0407”(direct interaction)	0.600
NR1D1	NCOR1	psi-mi:“MI:0915”(physical association)	0.600

BioGRID (716): NCOR1 (Affinity Capture-Western), NCOR1 (Protein-peptide), NCOR1 (Reconstituted Complex), NCOR1 (Two-hybrid), NCOR1 (Two-hybrid), NCOR1 (Two-hybrid), PPARD (Reconstituted Complex), THRB (Reconstituted Complex), PPARA (Reconstituted Complex), PPARG (Reconstituted Complex), NCOR1 (Reconstituted Complex), NCOR1 (Reconstituted Complex), NCOR1 (Reconstituted Complex), NCOR1 (Protein-peptide), NCOR1 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WPF7, A0A0R4IBL7, O09000, O54972, O70305, O75081, O75376, P15806, P15881, P15884, P15923, P21677, P30985, P51514, P98180, Q05AQ8, Q14157, Q14687, Q1LY51, Q2VPM4, Q3U3C9, Q4KKX4, Q4VCS5, Q566L4, Q5F3B1, Q5SFM8, Q5T6F2, Q60722, Q60974, Q61286, Q62655, Q6DIH5, Q7ZWN6, Q7ZXS3, Q80X50, Q86YP4, Q8BZ47, Q8CHY6, Q8IXK0, Q8VHG2

Diamond homologs: A5PJX4, O75376, Q3U3N0, Q3UHF3, Q4KKX4, Q4R3R9, Q5REE1, Q5UAK0, Q5ZKT9, Q60974, Q7T105, Q7Z3K6, Q8N108, Q8N344, Q9WU42, Q9Y618, P25357, Q0GGX2, Q4R2Z8, Q55DP9, Q59E36, Q5FWT8, Q6NRZ0, Q6P116, Q8C796, Q8CFE3, Q8IZ40, Q8QG78, Q90WN5, Q9H0D2, Q9H4R4, Q9P2K3, Q9UKL0, Q9WUB5, Q10369, Q5ZJ40, Q6PGA0, Q6PJG2, Q8BXJ2, Q96PN7

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
AKT1	down-regulates	NCOR1	phosphorylation
AKT	down-regulates	NCOR1	phosphorylation
NCOR1	“up-regulates activity”	BCL6	binding
SIRT1	up-regulates	NCOR1
NCOR1	“down-regulates quantity by repression”	PPARG	“transcriptional regulation”
NCOR1	“down-regulates quantity by repression”	SNAI2	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 174 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of intracellular receptors	9	24.0×	2e-08
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	8	19.6×	5e-07
Notch-HLH transcription pathway	6	19.4×	2e-05
Nuclear Receptor transcription pathway	12	19.1×	5e-10
RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	5	16.2×	3e-04
Regulation of MECP2 expression and activity	5	14.6×	4e-04
Regulation of endogenous retroelements	5	14.6×	4e-04
Expression of BMAL (ARNTL), CLOCK, and NPAS2	6	13.9×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
intracellular receptor signaling pathway	7	43.1×	3e-08
negative regulation of miRNA transcription	8	31.0×	3e-08
positive regulation of cholesterol efflux	5	19.4×	5e-04
intracellular glucose homeostasis	5	18.1×	6e-04
positive regulation of miRNA transcription	9	16.2×	5e-07
hormone-mediated signaling pathway	6	14.9×	3e-04
autophagosome maturation	6	13.1×	5e-04
mRNA transcription by RNA polymerase II	6	12.3×	6e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 13 cancer types — ALL, BLCA, BRCA, CHOL, DLBCLNOS, HNSC, LUAD, MBL, NBL, PLMESO, PRAD, PROSTATE…(+1 more).

Clinical variants and AI predictions

ClinVar

364 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	251
Likely benign	29
Benign	24

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
431697	NM_006311.4(NCOR1):c.97C>T (p.Arg33Cys)	Likely pathogenic

SpliceAI

7985 predictions. Top by Δscore:

Variant	Effect	Δscore
17:16034759:CCTTA:C	donor_loss	1.0000
17:16034760:CTTA:C	donor_loss	1.0000
17:16034761:TTAC:T	donor_loss	1.0000
17:16034762:TACC:T	donor_loss	1.0000
17:16034763:A:T	donor_loss	1.0000
17:16037724:C:CT	donor_gain	1.0000
17:16037725:T:TT	donor_gain	1.0000
17:16039429:GTAC:G	donor_loss	1.0000
17:16039430:TA:T	donor_loss	1.0000
17:16039431:AC:A	donor_loss	1.0000
17:16039432:C:CA	donor_loss	1.0000
17:16039650:TGAGC:T	acceptor_gain	1.0000
17:16039651:GAGC:G	acceptor_gain	1.0000
17:16039652:AGC:A	acceptor_gain	1.0000
17:16039655:C:CC	acceptor_gain	1.0000
17:16057734:TTTG:T	acceptor_gain	1.0000
17:16057735:TTG:T	acceptor_gain	1.0000
17:16057900:AACTT:A	donor_loss	1.0000
17:16057901:ACTT:A	donor_loss	1.0000
17:16057902:CTTAC:C	donor_loss	1.0000
17:16057904:TA:T	donor_loss	1.0000
17:16057905:A:AC	donor_gain	1.0000
17:16057905:A:C	donor_loss	1.0000
17:16057906:C:CG	donor_gain	1.0000
17:16057906:CA:C	donor_gain	1.0000
17:16057906:CACA:C	donor_gain	1.0000
17:16057906:CACAG:C	donor_gain	1.0000
17:16058060:ATCAT:A	acceptor_gain	1.0000
17:16058061:TCAT:T	acceptor_gain	1.0000
17:16058062:CAT:C	acceptor_gain	1.0000

AlphaMissense

15912 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:16039576:A:G	L2271P	1.000
17:16039580:C:G	A2270P	1.000
17:16039588:A:C	I2267S	1.000
17:16039588:A:G	I2267T	1.000
17:16039588:A:T	I2267N	1.000
17:16047016:A:T	V2205D	1.000
17:16047037:A:G	L2198P	1.000
17:16057730:A:T	I2059N	1.000
17:16057911:A:C	I2055S	1.000
17:16057911:A:T	I2055N	1.000
17:16061487:A:G	F1932S	1.000
17:16061811:A:G	L1824P	1.000
17:16061811:A:T	L1824H	1.000
17:16065589:T:A	D1616V	1.000
17:16065589:T:G	D1616A	1.000
17:16065595:A:G	L1614S	1.000
17:16065598:A:T	I1613N	1.000
17:16117919:A:G	L675P	1.000
17:16117930:C:A	R671S	1.000
17:16117930:C:G	R671S	1.000
17:16117931:C:A	R671M	1.000
17:16117933:T:A	K670N	1.000
17:16117933:T:G	K670N	1.000
17:16117934:T:A	K670I	1.000
17:16117935:T:C	K670E	1.000
17:16117939:G:C	N668K	1.000
17:16117939:G:T	N668K	1.000
17:16117942:A:C	F667L	1.000
17:16117942:A:T	F667L	1.000
17:16117944:A:G	F667L	1.000

dbSNP variants (sampled 300 via entrez): RS1000004842 (17:16141953 C>T), RS1000011767 (17:16109038 T>A,C), RS1000016361 (17:16146655 A>G), RS1000017823 (17:16093578 C>A), RS1000032419 (17:16132614 C>G), RS1000040711 (17:16130462 C>T), RS1000054974 (17:16029835 G>A), RS1000108325 (17:16147589 T>C), RS1000112284 (17:16188461 A>G), RS1000158034 (17:16108027 C>T), RS1000164039 (17:16215205 G>A), RS1000171678 (17:16173363 G>A), RS1000185453 (17:16135312 G>A), RS1000185637 (17:16189972 C>T), RS1000188297 (17:16141002 A>C)

Disease associations

OMIM: gene MIM:600849 | disease phenotypes: MIM:114480, MIM:615157

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal dominant
neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (6): breast ductal adenocarcinoma (MONDO:0005590), hereditary breast carcinoma (MONDO:0016419), mitochondrial complex III deficiency nuclear type 2 (MONDO:0014063), autism spectrum disorder (MONDO:0005258), complex neurodevelopmental disorder (MONDO:0100038), neurodevelopmental disorder (MONDO:0700092)

Orphanet (2): Hereditary breast cancer (Orphanet:227535), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST006896_13	Free thyroxine concentration	2.000000e-12
GCST007429_126	Lung function (FVC)	3.000000e-10
GCST007432_64	FEV1	7.000000e-09
GCST007614_1	C-reactive protein levels	3.000000e-08
GCST008480_12	Lung function (FEV1)	4.000000e-07
GCST010988_56	Adult body size	5.000000e-09
GCST90002388_487	Lymphocyte count	4.000000e-14

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004312	vital capacity
EFO:0004314	forced expiratory volume
EFO:0004458	C-reactive protein measurement
EFO:0004587	lymphocyte count

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D065886	Neurodevelopmental Disorders	F03.625
C562840	Breast Cancer, Familial (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2406898 (SINGLE PROTEIN), CHEMBL3038484 (PROTEIN COMPLEX), CHEMBL6195598 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 89,522 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL343448	ROMIDEPSIN	4	12,963
CHEMBL98	VORINOSTAT	4	50,361
CHEMBL272980	MOCETINOSTAT	2	3,884
CHEMBL99	TRICHOSTATIN	1	22,314

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

7 measured of 7 human assays (7 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
3-[5-[(4-chlorophenyl)methyl]-7-fluoro-4-oxo-1H-quinolin-2-yl]-4-methylsulfonylbenzonitrile	EC50	55 nM	US-20250186425: PPARG INVERSE AGONISTS AND USES THEREOF
3-[5-(4-chlorophenoxy)-7-fluoro-4-oxo-1H-quinolin-2-yl]-4-methylsulfonylbenzonitrile	EC50	550 nM	US-20250186425: PPARG INVERSE AGONISTS AND USES THEREOF
4-chloro-3-[5-(4-chlorophenoxy)-7-fluoro-4-oxo-1H-quinolin-2-yl]benzonitrile	EC50	550 nM	US-20250186425: PPARG INVERSE AGONISTS AND USES THEREOF
3-[7-chloro-5-(1-methylpyrazol-4-yl)oxy-4-oxo-1H-quinolin-2-yl]-4-methylsulfonylbenzonitrile	EC50	550 nM	US-20250186425: PPARG INVERSE AGONISTS AND USES THEREOF
4-chloro-3-[5-[(4-chlorophenyl)methoxy]-7-fluoro-4-oxo-1H-quinolin-2-yl]benzonitrile	EC50	550 nM	US-20250186425: PPARG INVERSE AGONISTS AND USES THEREOF
3-[7-fluoro-5-(1-methylpyrazol-4-yl)oxy-4-oxo-1H-quinolin-2-yl]-4-methylsulfonylbenzonitrile	EC50	5500 nM	US-20250186425: PPARG INVERSE AGONISTS AND USES THEREOF

ChEMBL bioactivities

79 potent at pChembl≥5 of 83 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.15	IC50	0.07	nM	CHEMBL4637689
10.06	IC50	0.087	nM	CHEMBL4641682
9.82	Ki	0.15	nM	ROMIDEPSIN
9.77	IC50	0.17	nM	CHEMBL4634501
9.27	Ki	0.54	nM	TRICHOSTATIN
9.17	IC50	0.67	nM	CHEMBL4170617
8.92	IC50	1.2	nM	CHEMBL4644307
8.70	IC50	2	nM	CHEMBL4647458
8.52	IC50	3	nM	CHEMBL113537
8.51	IC50	3.1	nM	CHEMBL4632775
8.49	IC50	3.2	nM	CHEMBL4637836
8.39	IC50	4.1	nM	CHEMBL4163681
8.15	IC50	7.1	nM	CHEMBL113537
8.01	IC50	9.8	nM	VORINOSTAT
8.00	Ki	9.9	nM	VORINOSTAT
7.96	IC50	11	nM	CHEMBL113537
7.96	Ki	11	nM	CHEMBL113537
7.92	IC50	12	nM	CHEMBL2407723
7.92	IC50	12	nM	CHEMBL2407717
7.92	Ki	12	nM	VORINOSTAT
7.89	IC50	13	nM	CHEMBL4632449
7.85	IC50	14	nM	CHEMBL2407736
7.85	Ki	14	nM	AZUMAMIDE C
7.82	IC50	15	nM	CHEMBL4641904
7.80	IC50	16	nM	CHEMBL2407719
7.77	IC50	17	nM	CHEMBL4159366
7.75	IC50	18	nM	CHEMBL113537
7.70	IC50	20	nM	CHEMBL4644721
7.66	IC50	22	nM	MOCETINOSTAT
7.64	IC50	23	nM	CHEMBL2407722
7.64	IC50	23	nM	CHEMBL4647164
7.60	Ki	25	nM	AZUMAMIDE E
7.52	IC50	30	nM	CHEMBL2407735
7.51	IC50	31	nM	CHEMBL2407730
7.44	IC50	36	nM	CHEMBL2407721
7.40	IC50	40	nM	CHEMBL2407731
7.35	IC50	45	nM	CHEMBL4160840
7.30	IC50	50	nM	CHEMBL4633968
7.29	IC50	51	nM	VORINOSTAT
7.28	IC50	52	nM	CHEMBL2407720
7.28	IC50	52	nM	CHEMBL113537
7.27	IC50	53.89	nM	VORINOSTAT
7.20	IC50	63	nM	CHEMBL2407716
7.16	IC50	70	nM	CHEMBL2407732
7.10	IC50	79	nM	CHEMBL2407718
7.10	IC50	79.17	nM	CHEMBL4781177
7.08	IC50	83	nM	CHEMBL2407734
7.05	IC50	90	nM	CHEMBL4639586
6.98	IC50	104	nM	CHEMBL2407733
6.97	IC50	106.3	nM	CHEMBL4790998

PubChem BioAssay actives

70 with measured affinity, of 98 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0001	uM
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(5-methyl-1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0001	uM
Romidepsin	765391: Inhibition of GST-tagged recombinant human HDAC3/NcoR1 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	ki	0.0001	uM
N-[(1S)-1-[5-(2-fluorophenyl)-1,3-oxazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0002	uM
2-[[7-(hydroxyamino)-7-oxoheptyl]-(3-methylbutyl)amino]-N-(3-imidazol-1-ylpropyl)-1,3-thiazole-5-carboxamide	1349715: Inhibition of human recombinant HDAC3/GST-tagged NCOR1 DAD (397 to 503 residues) expressed in baculovirus expression system after 30 mins by fluorescence assay	ic50	0.0007	uM
(7S)-7-amino-7-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-1-(1,2-oxazol-3-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0012	uM
N-[(1S)-1-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-7-oxo-7-(1,3-thiazol-2-yl)heptyl]-1-methylpiperidine-4-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0020	uM
N-[(1S)-1-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-7-(1,3-oxazol-2-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0031	uM
(7S)-7-amino-7-[5-(2-fluorophenyl)-1,2-oxazol-3-yl]-1-(1,2-oxazol-3-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0032	uM
2-[(4-fluorophenyl)methyl-[7-(hydroxyamino)-7-oxoheptyl]amino]-N-(3-imidazol-1-ylpropyl)-1,3-thiazole-5-carboxamide	1349715: Inhibition of human recombinant HDAC3/GST-tagged NCOR1 DAD (397 to 503 residues) expressed in baculovirus expression system after 30 mins by fluorescence assay	ic50	0.0041	uM
Vorinostat	1349715: Inhibition of human recombinant HDAC3/GST-tagged NCOR1 DAD (397 to 503 residues) expressed in baculovirus expression system after 30 mins by fluorescence assay	ic50	0.0098	uM
N-(2-aminophenyl)-4-[[[(4S)-4-phenyl-1,3-thiazolidin-2-ylidene]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0120	uM
N-(2-aminophenyl)-4-[[[(5S)-5-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0120	uM
(7S)-7-amino-7-[1-(4-fluorophenyl)pyrazol-4-yl]-1-(1,2-oxazol-3-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0130	uM
N-(2-aminophenyl)-4-[[(4-oxo-5-phenylimidazolidin-2-ylidene)amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0140	uM
(Z)-6-[(2R,5R,8R,11R,12S)-8-[(4-hydroxyphenyl)methyl]-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enoic acid	765391: Inhibition of GST-tagged recombinant human HDAC3/NcoR1 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	ki	0.0140	uM
(7S)-7-amino-7-[1-(4-fluorophenyl)pyrazol-3-yl]-1-(1,2-oxazol-3-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0150	uM
N-(2-aminophenyl)-4-[[[(4S)-4-(4-hydroxyphenyl)-1,3-thiazolidin-2-ylidene]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0160	uM
N-[8-(hydroxyamino)-8-oxooctyl]-1-[4-[[4-[4-(methanesulfonamido)phenyl]pyrimidin-2-yl]amino]phenyl]piperidine-4-carboxamide	1355684: Inhibition of human recombinant HDAC3/GST-tagged NCOR1 (397 to 503 residues) co-expressed in insect cells using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	ic50	0.0170	uM
(7S)-7-amino-7-[2-(4-fluorophenyl)triazol-4-yl]-1-(1,2-oxazol-3-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0200	uM
N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0220	uM
N-[(1S)-1-[5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0230	uM
N-(2-aminophenyl)-4-[[[(5R)-5-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0230	uM
(Z)-6-[(2R,5R,8R,11R,12S)-8-benzyl-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enoic acid	765391: Inhibition of GST-tagged recombinant human HDAC3/NcoR1 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	ki	0.0250	uM
N-(2-aminophenyl)-4-[[(4-benzyl-5-oxoimidazolidin-2-ylidene)amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0300	uM
N-hydroxy-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0310	uM
N-(2-aminophenyl)-4-[[[(4R)-4-benzyl-1,3-thiazolidin-2-ylidene]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0360	uM
tert-butyl 2-[[4-[(2-aminophenyl)carbamoyl]phenyl]methylimino]-5-(1H-indol-3-ylmethyl)-4-oxoimidazolidine-1-carboxylate	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0400	uM
N-hydroxy-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide	1355684: Inhibition of human recombinant HDAC3/GST-tagged NCOR1 (397 to 503 residues) co-expressed in insect cells using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	ic50	0.0450	uM
N-[(1S)-1-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-7-(4-methyl-1,3-oxazol-2-yl)-7-oxoheptyl]-1-methylpiperidine-4-carboxamide	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0500	uM
N-(2-aminophenyl)-4-[[[(4S)-4-benzyl-1,3-thiazolidin-2-ylidene]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0520	uM
N-(2-aminophenyl)-4-[[(4S)-4-phenyl-4,5-dihydro-1,3-thiazol-2-yl]sulfanylmethyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0630	uM
4-[[[1-acetyl-5-(1H-indol-3-ylmethyl)-4-oxoimidazolidin-2-ylidene]amino]methyl]-N-(2-aminophenyl)benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0700	uM
N-(2-aminophenyl)-4-[[[(4R)-4-phenyl-1,3-thiazolidin-2-ylidene]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0790	uM
6-[4-[5,7-dimethoxy-4-(4-methylpiperazin-1-yl)quinazolin-2-yl]-2,6-dimethylphenoxy]-N-hydroxyhexanamide	1742179: Inhibition of recombinant human GST-fused HDAC3/NCOR1 (397 to 503 residues) expressed in baculovirus infected insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	ic50	0.0792	uM
4-[[(1-acetyl-5-benzyl-4-oxoimidazolidin-2-ylidene)amino]methyl]-N-(2-aminophenyl)benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.0830	uM
(7S)-7-amino-7-[5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl]-1-(5-methyl-1,2-oxazol-4-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0900	uM
N-(2-aminophenyl)-4-[[[4-(1H-indol-3-ylmethyl)-5-oxoimidazolidin-2-ylidene]amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.1040	uM
6-[4-[4-(1,1-dioxo-1,4-thiazinan-4-yl)-5,7-dimethoxyquinazolin-2-yl]-2,6-dimethylphenoxy]-N-hydroxyhexanamide	1742179: Inhibition of recombinant human GST-fused HDAC3/NCOR1 (397 to 503 residues) expressed in baculovirus infected insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	ic50	0.1063	uM
N-(2-amino-4-methoxyphenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide	762203: Inhibition of recombinant HDAC3-NCoR1 (unknown origin) using MAL as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis	ic50	0.1110	uM
(7S)-7-amino-1-[5-(hydroxymethyl)-1,3-oxazol-2-yl]-7-[5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl]heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.1200	uM
N-(2-aminophenyl)-4-[(4-methoxyphenyl)sulfanylmethyl]benzamide	1598961: Inhibition of recombinant human HDAC3/NCOR1 assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate preincubated for 10 mins followed by substrate addition and and measured after 30 mins by fluorescence based assay	ic50	0.1360	uM
(7S)-7-amino-7-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-1-(1,3-oxazol-4-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.1500	uM
N-(2-aminophenyl)-4-[(4-ethylphenyl)sulfanylmethyl]benzamide	1598961: Inhibition of recombinant human HDAC3/NCOR1 assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate preincubated for 10 mins followed by substrate addition and and measured after 30 mins by fluorescence based assay	ic50	0.2150	uM
(7S)-7-amino-7-[5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl]-1-(1H-pyrazol-5-yl)heptan-1-one	1664942: Inhibition of full length human recombinant FLAG-tagged HDAC3/His6-tagged SMRT (1 to 899 residues) expressed in HEK293F cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.2300	uM
N-[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]-1-[4-[[4-[4-(methanesulfonamido)phenyl]pyrimidin-2-yl]amino]phenyl]piperidine-4-carboxamide	1355684: Inhibition of human recombinant HDAC3/GST-tagged NCOR1 (397 to 503 residues) co-expressed in insect cells using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	ic50	0.2340	uM
N-(2-amino-5-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide	1598961: Inhibition of recombinant human HDAC3/NCOR1 assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate preincubated for 10 mins followed by substrate addition and and measured after 30 mins by fluorescence based assay	ic50	0.2340	uM
N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)triazol-4-yl]benzamide	1525484: Inhibition of recombinant human HDAC3/GST-tagged NCOR1 DAD (397 to 503 residues) expressed in baculovirus expression system using Fluor de Lys as substrate by fluorescence assay	ic50	0.2400	uM
N-(2-aminophenyl)-5-[1-[2-(3-nitrophenyl)ethyl]triazol-4-yl]thiophene-2-carboxamide	1454717: Inhibition of human recombinant HDAC3/NCOR1 co-expressed in insect cells by fluorescence assay	ic50	0.2600	uM
N-(2-aminophenyl)-4-[[4-(trifluoromethyl)pyrimidin-2-yl]sulfanylmethyl]benzamide	1598961: Inhibition of recombinant human HDAC3/NCOR1 assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate preincubated for 10 mins followed by substrate addition and and measured after 30 mins by fluorescence based assay	ic50	0.2740	uM

CTD chemical–gene interactions

85 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects binding, affects reaction, decreases reaction, increases reaction	9
bisphenol A	affects reaction, affects cotreatment, increases methylation, decreases reaction, decreases activity (+2 more)	7
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression, decreases methylation	7
Tamoxifen	affects binding, decreases reaction, increases reaction	4
Fulvestrant	increases expression, affects cotreatment, increases methylation, decreases expression, affects binding (+2 more)	3
Calcitriol	affects binding, decreases reaction, increases reaction, affects cotreatment, increases activity (+1 more)	3
lithocholic acid acetate	increases reaction, decreases reaction, affects cotreatment, increases activity, increases expression (+1 more)	2
bisphenol S	affects binding, decreases reaction, affects cotreatment, decreases expression	2
bisphenol AF	decreases reaction, affects binding, affects folding, increases reaction	2
Acetaminophen	decreases expression	2
Dihydrotestosterone	affects binding, decreases reaction, increases activity	2
Cyproterone Acetate	decreases reaction, increases reaction, affects binding, affects folding	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
moringin	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
pirinixic acid	affects binding, decreases reaction	1
geraniol	increases expression	1
methylselenic acid	affects binding, decreases reaction	1
tetraiodothyroacetic acid	affects binding, decreases reaction	1
plastochromanol 8	affects binding, decreases reaction	1
arsenite	decreases reaction, increases expression, decreases expression	1
mono-(2-ethylhexyl)phthalate	affects binding, decreases reaction	1
afimoxifene	affects binding, increases reaction	1
butyraldehyde	decreases expression	1
coumarin	affects phosphorylation	1
dicyclohexyl phthalate	affects binding, decreases reaction	1

ChEMBL screening assays

31 unique, capped per target: 31 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5582661	Binding	Effect on NCoR recruitment (unknown origin) at 10 uM incubated for 24 hrs by TR-FRET assay	Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ. — J Med Chem

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B371	TL-1	Cancer cell line	Male
CVCL_E0IS	Ubigene HeLa NCOR1 KO	Cancer cell line	Female
CVCL_KZ59	PathHunter HEK 293 LXRbeta-NCoR1 Protein Interaction	Transformed cell line	Female

Clinical trials (associated diseases)

500 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD